Emapalumab is human monoclonal antibody against IFN-γ that is FDA-approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH), a rare genetic disorder resulting in the overproduction of cytokines by histocytes and lymphocytes [38]. This evidence concerns the gene IFNG and hemophagocytic syndrome.